Study of MLN4924 in Adult Patients With Nonhematologic Malignancies

Inclusion Criteria: * Male or female patients 18 years or older * Eastern Cooperative Oncology Group performance status 0-2 * Patients must have a diagnosis of a nonhematologic malignancy for which standard curative, life-prolonging, or palliative treatment does not exist or is no longer effective. * Expected survival longer than 6 weeks from enrollment in the study * Radiographically or clinically evaluable tumor * Suitable venous access for the conduct of blood sampling for MLN4924 * Tumor tissue that, in the opinion of the investigator, can be safely biopsied using a core needle * Male patients must use an appropriate method of barrier contraception * Female patients must be postmenopausal, surgically sterilized, or willing to use reliable methods of birth control * Voluntary written consent Exclusion Criteria: * Pregnant or lactating * Major surgery within 14 days prior to the first dose of study treatment * Serious infection within 14 days prior to the first dose of study treatment * Receiving antibiotic therapy within 14 days prior to the first dose of study treatment * Life-threatening illness unrelated to cancer * Diarrhea that is greater than Grade 1 in severity * Systemic antineoplastic therapy within 21 days preceding first dose of study treatment * Radiotherapy within 21 days preceding first dose of study treatment * Prior treatment with radiation therapy involving ≥25% of the hematopoietically active bone marrow * CYP3A inducers within 14 days before the first dose of MLN4924. Moderate and strong CYP3A inhibitors and CYP3A inducers are not permitted during the study. * Clinically significant central nervous system metastases * Absolute neutrophil count \<1,500/mm3; platelet count \<100,000/mm3 * Patients with a prothrombin time or aPTT \> 1.5 x the upper limit of the normal range, or with a history of a coagulopathy or bleeding disorder * Ongoing anti-coagulant therapy that can not be held to permit tumor biopsy * Calculated creatinine clearance \<50 mL/minute * Bilirubin \>1.5 times the upper limit of normal; aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase \>2.5 times the upper limit of normal. * Uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months * Abnormalities on 12-lead electrocardiogram including, but not limited to, changes in rhythm and intervals that in the opinion of the investigator are considered to be clinically significant * Known human immunodeficiency virus positive or hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection * Treatment with any investigational products within 28 days preceding the first dose of study treatment